DexCom, Inc. (NASDAQ:DXCM) Position Increased by ICICI Prudential Asset Management Co Ltd

ICICI Prudential Asset Management Co Ltd lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 19.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,231 shares of the medical device company’s stock after acquiring an additional 863 shares during the period. ICICI Prudential Asset Management Co Ltd’s holdings in DexCom were worth $351,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Empowered Funds LLC raised its stake in DexCom by 30.7% during the 1st quarter. Empowered Funds LLC now owns 5,518 shares of the medical device company’s stock valued at $765,000 after purchasing an additional 1,295 shares during the period. QRG Capital Management Inc. raised its position in DexCom by 10.6% during the first quarter. QRG Capital Management Inc. now owns 10,896 shares of the medical device company’s stock valued at $1,511,000 after buying an additional 1,046 shares during the period. Avantax Advisory Services Inc. lifted its stake in DexCom by 35.4% in the 1st quarter. Avantax Advisory Services Inc. now owns 3,601 shares of the medical device company’s stock worth $499,000 after acquiring an additional 942 shares in the last quarter. Bleakley Financial Group LLC boosted its position in DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares during the period. Finally, Kingsview Wealth Management LLC boosted its position in DexCom by 4.3% during the 1st quarter. Kingsview Wealth Management LLC now owns 14,880 shares of the medical device company’s stock worth $2,064,000 after acquiring an additional 613 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 2.4 %

DXCM opened at $72.53 on Thursday. The company has a market capitalization of $28.33 billion, a P/E ratio of 43.43, a P/E/G ratio of 2.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm’s fifty day moving average price is $69.72 and its two-hundred day moving average price is $92.27. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

Analyst Upgrades and Downgrades

Several analysts have commented on DXCM shares. Barclays decreased their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. UBS Group decreased their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Sanford C. Bernstein increased their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Royal Bank of Canada reduced their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, BTIG Research decreased their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

Insider Activity

In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.